![How to Find Low-Competition Keywords with Semrush [Super Easy]](https://static.semrush.com/blog/uploads/media/73/62/7362f16fb9e460b6d58ccc09b4a048b6/how-to-find-low-competition-keywords-sm.png)
2 Top Growth Stocks to Buy and Hold for the Next 20 Years
One of the keys to successful investing is holding shares of companies that can perform well over long periods. However, few companies can thrive for that long while delivering excellent returns to investors. Those that do tend to have some key attributes, including a strong moat and attractive growth opportunities.Looking for stocks that fit this description? Let's consider two great examples: Eli Lilly (NYSE: LLY) and Veeva Systems (NYSE: VEEV). Here's what investors need to know about these market leaders that could deliver outsized returns in the next two decades.Eli Lilly is grabbing headlines thanks to medicines like Mounjaro for diabetes and Zepbound for weight management. However, these therapies will run out of patent protection and stop being growth drivers well before 2045. The company's long-term prospects don't depend on a couple of drugs but on Eli Lilly's culture of innovation. It has remained a leader in the market for diabetes medicines for decades and has routinely made significant breakthroughs -- or at least kept up with the ones made by its main rival, Novo Nordisk.Continue reading
One of the keys to successful investing is holding shares of companies that can perform well over long periods. However, few companies can thrive for that long while delivering excellent returns to investors. Those that do tend to have some key attributes, including a strong moat and attractive growth opportunities.
Looking for stocks that fit this description? Let's consider two great examples: Eli Lilly (NYSE: LLY) and Veeva Systems (NYSE: VEEV). Here's what investors need to know about these market leaders that could deliver outsized returns in the next two decades.
Eli Lilly is grabbing headlines thanks to medicines like Mounjaro for diabetes and Zepbound for weight management. However, these therapies will run out of patent protection and stop being growth drivers well before 2045. The company's long-term prospects don't depend on a couple of drugs but on Eli Lilly's culture of innovation. It has remained a leader in the market for diabetes medicines for decades and has routinely made significant breakthroughs -- or at least kept up with the ones made by its main rival, Novo Nordisk.
